Pimavanserin(CAS#706779-91-1)
| Hazard Symbols | Xi – Irritant |
| Safety Description | 24/25 – Avoid contact with skin and eyes. |
| HS Code | 29339900 |
pharmachologic effect
Receptor selectivity: is a selective, potent serotonin 2A (5-HT2A) receptor inverse agonist with approximately 40-fold greater affinity for the 5-HT2A receptor than for the 5-HT2C receptor.
Mechanism of disease treatment: It acts by selectively inhibiting the 5-HT2a receptor, which plays a key role in the occurrence of hallucinations and delusions, and can be used to treat psychiatric symptoms such as delusions, hallucinations, and delusions associated with Parkinson’s disease, and can also inhibit amyloid β protein production, which has an ameliorating effect on anxiety-related behaviors and memory in mouse models of Alzheimer’s disease.
Clinical application
Treatment of psychiatric symptoms of Parkinson’s disease: Approved by the U.S. Food and Drug Administration on April 29, 2016, for the treatment of psychiatric symptoms associated with Parkinson’s disease, it has a lower incidence of side effects, especially extrapyramidal symptoms, compared with other antipsychotic drugs.
Dementia-related psychosis therapeutic potential: In a clinical trial called “harmony”, it has shown the potential to significantly reduce the risk of relapse of dementia-related psychosis.
